Centre Hospitalier Regional Universitaire De Tours
Verified
Tours, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical study aims to improve pain management for individuals with sickle cell disease who are experiencing vaso-occlusive crisis and/or acute chest syndrome while in intensive care. Sickle cell disease is an inherited blood disorder where red blood cells become crescent-shaped and can block blood vessels, causing severe pain episodes. The study focuses on how the kidneys process morphine, which is commonly used to treat severe pain in these patients.
The research evaluates how well the kidneys filter blood (called glomerular filtration) and how this affects morphine processing in the body. By measuring kidney function using iohexol clearance (a reference method) and comparing it to a kidney function estimation tool (CKD-Epi score), researchers hope to determine when standard morphine doses might not provide adequate pain relief for certain patients.
Understanding the relationship between kidney function and morphine effectiveness could help doctors identify which patients need higher initial doses of pain medication. This would allow for more personalized pain management strategies for people with sickle cell disease during painful crises, potentially improving treatment outcomes and patient comfort.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
9 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Tours, France
Nantes, France
Rennes, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
A potent opioid analgesic administered intravenously for managing severe pain, particularly in sickle cell patients experiencing vaso-occlusive crises. It works by binding to opioid receptors in the brain and spinal cord, altering the perception of and emotional response to pain. Morphine is classified as a full opioid agonist and remains a cornerstone treatment for acute severe pain, though its effectiveness can be affected by kidney function since it is primarily eliminated through the kidneys. In patients with reduced glomerular filtration, dosage adjustments may be necessary to prevent accumulation of the drug and its metabolites, which could lead to side effects or inadequate pain control.
A non-ionic, water-soluble radiographic contrast agent used in this study as a reference method for accurately measuring glomerular filtration rate (GFR). When administered intravenously, iohexol is filtered exclusively by the kidneys without being secreted or reabsorbed, making its clearance rate an excellent marker of kidney function. This contrast medium is widely accepted in medical literature as a gold standard for GFR assessment and provides more precise measurements than estimated GFR calculations based on serum creatinine. By using iohexol clearance, researchers can obtain reliable data about kidney function to correlate with morphine effectiveness in sickle cell patients.
Sickle cell disease is an inherited blood disorder characterized by abnormal hemoglobin that causes red blood cells to become rigid and C-shaped (sickle-shaped). These abnormal cells can block blood vessels, reducing blood flow and oxygen to body tissues. The disease is marked by episodes of intense pain called vaso-occlusive crises that occur when sickle cells block small blood vessels. Over time, sickle cell disease can affect multiple organs including the lungs, kidneys, spleen, and bones. The condition typically manifests in early childhood and varies in severity among affected individuals.
Chronic kidney disease is a condition characterized by gradual loss of kidney function over time. The kidneys filter wastes and excess fluids from the blood, which are then excreted in urine. As kidney function declines, waste products accumulate in the blood. The disease progresses through five stages of increasing severity based on glomerular filtration rate (GFR). CKD may initially present with few symptoms but can eventually lead to complications like high blood pressure, anemia, bone disease, and fluid buildup. The condition develops slowly over months or years and may result from various underlying causes.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.